Peptide Protocol
Peptide Protocol
 App Store

CJC-1295: the complete guide

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It stimulates the pituitary to release endogenous growth hormone in a pulsatile fashion.

Written by Peptide Protocol Editorial Medically reviewed per our review process Last reviewed
ClassGHRH analog (growth-hormone-releasing hormone)
Half-lifeNo-DAC: ~30 minutes. DAC version: ~6–8 days.
Typical dose100 mcg, 1–3x daily (no-DAC); 1–2 mg weekly (DAC)
CategoryGrowth hormone axis
Research useGH axis research, recovery, body composition
FDA statusNot FDA approved. Research use only.

How CJC-1295 works

CJC-1295 binds to pituitary GHRH receptors, increasing GH pulse amplitude. The DAC-conjugated version has extended half-life through albumin binding.

Typical CJC-1295 dosage

Commonly reported research ranges: 100 mcg, 1–3x daily (no-DAC); 1–2 mg weekly (DAC).

Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.

How to reconstitute CJC-1295

A widely used reconstitution for a 2 mg vial is 2 ml of bacteriostatic water. With a typical 100 mcg dose this works out to the unit count shown in the calculator below.

Open the CJC-1295 reconstitution calculator →

Pre-filled with the common 2 mg + 2 ml ratio. Adjust for your own vial.

Half-life and administration frequency

No-DAC: ~30 minutes. DAC version: ~6–8 days..

This half-life informs how often CJC-1295 is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.

Reported side effects

This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.

Common CJC-1295 stacks

Full editorial stack guides featuring CJC-1295:

CJC-1295 + Ipamorelin

Recomposition, sleep quality, recovery, anti-aging protocols.

GH axisRecovery

CJC-1295 + Tesamorelin

Experimental protocols only. Most users are better served running Tesamorelin + Ipamorelin or CJC-1295 + Ipamorelin.

GH axisAdvanced

Storage and handling

Lyophilized refrigerated. Reconstituted: refrigerated, use within 28 days.

FDA and regulatory status

Not FDA approved. Research use only.

CJC-1295 clinical trials and evidence

For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.

Track your CJC-1295 protocol on iPhone

Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.

See the app →

Frequently asked questions

What is CJC-1295?

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It stimulates the pituitary to release endogenous growth hormone in a pulsatile fashion.

How does CJC-1295 work?

CJC-1295 binds to pituitary GHRH receptors, increasing GH pulse amplitude. The DAC-conjugated version has extended half-life through albumin binding.

What is a typical CJC-1295 dose?

Commonly reported ranges are 100 mcg, 1–3x daily (no-DAC); 1–2 mg weekly (DAC). This is research information, not a recommendation — dosing should be individualized under clinical guidance.

What is the half-life of CJC-1295?

No-DAC: ~30 minutes. DAC version: ~6–8 days.. This influences how often it is administered.

How do you reconstitute CJC-1295?

A common approach is to add 2 ml of bacteriostatic water to a 2 mg vial. Use the reconstitution calculator for exact unit counts.

What are the side effects of CJC-1295?

Flushing; Injection-site reactions; Headache; Transient water retention.

Is CJC-1295 FDA approved?

Not FDA approved. Research use only.

Are there clinical trials for CJC-1295?

Registered or published clinical-trial sources for CJC-1295 are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.

References

  1. CJC-1295 literature (PubMed) — National Library of Medicine. Primary research on CJC-1295 as a DAC-modified GHRH analog; sustained GH release profile
  2. Teichman et al. — Prolonged stimulation of GH and IGF-I secretion by CJC-1295 — PubMed. Key human pharmacokinetic study for CJC-1295 with DAC
  3. GHRH analog clinical trial records — ClinicalTrials.gov. Registered human studies referencing CJC-1295

Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.

Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.